A phase I multicenter study of antroquinonol in patients with metastatic non-small-cell lung cancer who have received at least two prior systemic treatment regimens, including one platinum-based chemotherapy regimen

Lee,Yu-Chin; Ho,Ching-Liang; Kao,Woei-Yau; Chen,Yuh-Min

doi:10.3892/mco.2015.642

November-2015 Volume 3 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November-2015 Volume 3 Issue 6

Full Size Image

Article

A phase I multicenter study of antroquinonol in patients with metastatic non-small-cell lung cancer who have received at least two prior systemic treatment regimens, including one platinum-based chemotherapy regimen

Authors:
- Yu-Chin Lee
- Ching-Liang Ho
- Woei-Yau Kao
- Yuh-Min Chen
View Affiliations / Copyright

Affiliations: Sijhih Cathay General Hospital, New Taipei 221, Taiwan, R.O.C., Tri‑Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan, R.O.C., Taipei Tzu Chi General Hospital, Taipei 231, Taiwan, R.O.C., School of Medicine, National Yang‑Ming University, Taipei 112, Taiwan, R.O.C.
Pages: 1375-1380
|
Published online on: September 15, 2015

https://doi.org/10.3892/mco.2015.642
Expand metrics +

Abstract

Antroquinonol is isolated from Antrodia camphorata, a camphor tree mushroom, and is a valuable traditional Chinese herbal medicine that exhibits pharmacological activities against several diseases, including cancer. this first‑in-human phase I study of antroquinonol included patients with metastatic non-small‑cell lung cancer who had received at least two prior systemic treatment regimens. An open-label, dose escalation, pharmacokinetic (PK) study was conducted to determine the maximum tolerable dose (MTD), dose-limiting toxicities (DLTs), and safety/tolerability and preliminary efficacy profiles of antroquinonol. The patients received escalating doses of once-daily antroquinonol in 4-week cycles (up to 3 cycles). The escalated doses were 50‑600 mg. PKs were evaluated on day 1 and 28 of cycle 1. Between January, 2011 and October, 2012, 13 patients with metastatic adenocarcinoma were enrolled. No DLTs occurred in any patient at any dose level. Tmax was observed between 1.00 and 3.70 h under single‑dose conditions, and at 1.92‑4.05 h under multiple‑dose conditions. The mean elimination half‑life ranged between 1.30 and 4.33 h, independent of the treatment dose. Antroquinonol at all dose levels had a mild toxicity profile, with no reported treatment-related mortality. The most common treatment-related adverse events were diarrhea, vomiting and nausea. The best tumor response was stable disease in 3 patients. In conclusion, antroquinonol at all dose levels, administered daily for 4 weeks, was generally safe and well tolerated, without DLTs. The recommended dose level for a phase II study is ≥600 mg daily.

View Figures

View References

1	Pfister DG, Johnson DH, Azzoli CG, et al: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 22:330–353. 2004. View Article : Google Scholar : PubMed/NCBI
2	Chiou JF, Wu AT, Wang WT, Kuo TH, Gelovani JG, Lin IH, Wu CH, Chiu WT and Deng WP: A preclinical evaluation of Antrodia camphorata alcohol extracts in the treatment of non-small cell lung cancer using non-invasive molecular imaging. Evid Based Complement Alternat Med. 2011:9145612011. View Article : Google Scholar : PubMed/NCBI
3	Chiang PC, Lin SC, Pan SL, Kuo CH, Tsai IL, Kuo MT, Wen WC, Chen P and Guh JH: Antroquinonol displays anticancer potential against human hepatocellular carcinoma cells: a crucial role of AMPK and mTOR pathways. Biochem Pharmacol. 79:162–171. 2010. View Article : Google Scholar : PubMed/NCBI
4	Yu CC, Chiang PC, Lu PH, Kuo MT, Wen WC, Chen P and Guh JH: Antroquinonol, a natural ubiquinone derivative, induces a cross talk between apoptosis, autophagy and senescence in human pancreatic carcinoma cells. J Nutrition Biochem. 23:900–907. 2012. View Article : Google Scholar
5	Kumar VB, Yuan TC, Liou JW, Yang CJ, Sung PJ and Weng CF: Antroquinonol inhibits NSCLC proliferation by altering PI3K/mTOR proteins and miRNA expression profiles. Mutation Res. 707:42–52. 2011. View Article : Google Scholar : PubMed/NCBI
6	Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
7	Chen CC, Shiao YJ, Lin RD, Shao YY, Lai MN, Lin CC, Ng LT and Kuo YH: Neuroprotective diterpenes from the fruiting body of Antrodia camphorata. J Nat Prod. 69:689–691. 2006. View Article : Google Scholar : PubMed/NCBI
8	Lee TH, Lee CK, Tsou WL, Liu SY, Kuo MT and Wen WC: A new cytotoxic agent from solid-state fermented mycelium of Antrodia camphorata. Planta Med. 73:1412–1415. 2007. View Article : Google Scholar : PubMed/NCBI
9	Hseu YC, Chang WC, Hseu YT, Lee CY, Yech YJ, Chen PC and Yang HL: Protection of oxidative damage by aqueous extract from Antrodia camphorata mycelia in normal human erythrocytes. Life Sci. 71:469–482. 2002. View Article : Google Scholar : PubMed/NCBI
10	Chang JM, Lee YR, Hung LM, Liu SY, Kuo MT, Wen WC and Chen P: An extract of Antrodia camphorata mycelia attenuates the progression of nephritis in systemic lupus erythematosus-prone NZB/W F1 mice. Evid Based Complement Alternat Med. 2011:4658942011. View Article : Google Scholar : PubMed/NCBI
11	Song TY and Yen GC: Protective effects of fermented filtrate from Antrodia camphorata in submerged culture against CC14-induced hepatic toxicity in rats. J Agric Food Chem. 51:1571–1577. 2003. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

A phase I multicenter study of antroquinonol in patients with metastatic non-small-cell lung cancer who have received at least two prior systemic treatment regimens, including one platinum-based chemotherapy regimen

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles